Metabolic and cardiovascular adverse effects associated with antipsychotic drugs

被引：0
|
作者：
Marc De Hert
Johan Detraux
Ruud van Winkel
Weiping Yu
Christoph U. Correll
机构：
[1] University Psychiatric Center,Department of Psychiatry and Psychology
[2] Catholic University Leuven,undefined
[3] South Limburg Mental Health Research and Teaching Network,undefined
[4] Maastricht University Medical Center,undefined
[5]  The Zucker Hillside Hospital,undefined
[6] Psychiatry Research,undefined
来源：
Nature Reviews Endocrinology | 2012年 / 8卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The contribution of antipsychotic medications to an increased risk of type 2 diabetes mellitus and cardiovascular disease is controversial. Despite existing guidelines and recommendations, many antipsychotic-drug-treated patients are not routinely assessed for metabolic and cardiac risk factors. This Review outlines the metabolic and cardiovascular risks of various antipsychotic medications in adults and children, defines the disparities in health care and makes recommendations for screening and monitoring of patients taking these agents.
引用
收藏
页码：114 / 126
页数：12
相关论文
共 50 条
  • [41] Targeted clinical audit of anti-cholinergic treatments prescribed for the adverse neurological effects associated with antipsychotic drugs
    Leroy, Caroline
    Dizet, Sophie
    Besson, Gerard
    Varnier, Virginie
    ANNALES MEDICO-PSYCHOLOGIQUES, 2019, 177 (05): : 408 - 412
  • [42] Adverse metabolic effects of antihypertensive drugs - Implications for treatment
    Preuss, HG
    Burris, JF
    DRUG SAFETY, 1996, 14 (06) : 355 - 364
  • [43] EFFECTS OF SOME ANTIPSYCHOTIC-DRUGS ON CARDIOVASCULAR CATECHOLAMINE RECEPTORS IN THE RAT
    CUFFI, ML
    VILA, E
    BADIA, A
    JOURNAL OF AUTONOMIC PHARMACOLOGY, 1989, 9 (06): : 397 - 409
  • [44] Metabolic disease and cardiovascular risk in psychiatric out-patients taking antipsychotic drugs
    Mackin, Paul
    Bishop, David
    Gallagher, Peter
    Watkinson, Helen M. O.
    Ferrier, Ian N.
    BIOLOGICAL PSYCHIATRY, 2007, 61 (08) : 166S - 166S
  • [45] Metabolic Consequences of Atypical Antipsychotic Drugs
    Harold E. Lebovitz
    Psychiatric Quarterly, 2003, 74 : 277 - 290
  • [46] Schizophrenia, antipsychotic drugs, and cardiovascular disease
    Glassman, AH
    JOURNAL OF CLINICAL PSYCHIATRY, 2005, 66 : 5 - 10
  • [47] Long-term metabolic and cardiovascular effects of antipsychotic drugs. A meta-analysis of randomized controlled trials
    Rotella, Francesco
    Cassioli, Emanuele
    Calderani, Enrico
    Lazzeretti, Lisa
    Ragghianti, Benedetta
    Ricca, Valdo
    Mannucci, Edoardo
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2020, 32 : 56 - 65
  • [48] Metabolic consequences of atypical antipsychotic drugs
    Lebovitz, HE
    PSYCHIATRIC QUARTERLY, 2003, 74 (03) : 277 - 290
  • [49] Structural contributions of antipsychotic drugs to their therapeutic profiles and metabolic side effects
    Jafari, Somayeh
    Fernandez-Enright, Francesca
    Huang, Xu-Feng
    JOURNAL OF NEUROCHEMISTRY, 2012, 120 (03) : 371 - 384
  • [50] Cardiac adverse effects associated with psychotropic drugs
    Schmid, C
    Grohmann, R
    Engel, RR
    Rüther, E
    Kropp, S
    PHARMACOPSYCHIATRY, 2004, 37 : S65 - S69
12345